$DYAI
DYADIC INTERNATIONAL INC

2021 Q4 Form 10-Q Financial Statement

#000143774921026157 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $313.3K $692.9K $416.4K
YoY Change -10.49% 66.43% -8.39%
Cost Of Revenue $331.6K $392.5K $266.9K
YoY Change 27.55% 47.06% -30.63%
Gross Profit -$18.34K $300.4K $149.4K
YoY Change -120.38% 101.02% 114.38%
Gross Profit Margin -5.85% 43.35% 35.89%
Selling, General & Admin $1.703M $1.693M $1.640M
YoY Change 30.01% 3.22% 54.72%
% of Gross Profit 563.56% 1097.49%
Research & Development $2.473M $1.902M $986.1K
YoY Change 144.9% 92.84% 17.2%
% of Gross Profit 633.04% 659.87%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.177M $1.902M $986.1K
YoY Change 80.81% 92.84% 17.2%
Operating Profit -$4.195M -$3.324M -$2.576M
YoY Change 88.96% 29.02% 32.57%
Interest Expense $1.587M $3.202K $76.81K
YoY Change 428.88% -95.83% -68.65%
% of Operating Profit
Other Income/Expense, Net -$1.606M $1.609M $76.81K
YoY Change 1994.46%
Pretax Income -$4.214M -$1.715M -$2.500M
YoY Change 118.33% -31.39% 47.06%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.214M -$1.715M -$2.499M
YoY Change 114.99% -31.38% 47.17%
Net Earnings / Revenue -1345.03% -247.54% -600.32%
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$150.0K -$61.09K -$90.98K
COMMON SHARES
Basic Shares Outstanding 28.08M 28.08M 27.48M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $20.26M $22.75M $30.41M
YoY Change -30.35% -25.2% -14.24%
Cash & Equivalents $15.75M $13.66M $21.86M
Short-Term Investments $4.512M $9.087M $8.540M
Other Short-Term Assets $375.8K $570.0K $420.0K
YoY Change 34.23% 35.71% 425.0%
Inventory
Prepaid Expenses
Receivables $277.8K $179.6K $806.8K
Other Receivables $94.38K $74.80K $100.0K
Total Short-Term Assets $21.01M $23.57M $31.74M
YoY Change -29.46% -25.73% -12.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $284.7K $284.7K $0.00
YoY Change 1.68% -100.0%
Other Assets $6.117K $6.143K $5.558K
YoY Change -1.73% 10.53% -88.94%
Total Long-Term Assets $290.8K $290.9K $5.558K
YoY Change -0.04% 5133.03% -99.73%
TOTAL ASSETS
Total Short-Term Assets $21.01M $23.57M $31.74M
Total Long-Term Assets $290.8K $290.9K $5.558K
Total Assets $21.30M $23.86M $31.75M
YoY Change -29.17% -24.83% -17.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.548M $957.8K $976.8K
YoY Change 52.79% -1.94% 36.92%
Accrued Expenses $709.6K $842.5K $620.6K
YoY Change 44.88% 35.74% 32.02%
Deferred Revenue $151.1K $162.7K $153.9K
YoY Change 22.87% 5.74% 64.95%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.556M $1.963M $1.751M
YoY Change 57.19% 12.09% 37.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $352.9K
YoY Change
Total Long-Term Liabilities $352.9K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.556M $1.963M $1.751M
Total Long-Term Liabilities $352.9K $0.00 $0.00
Total Liabilities $2.909M $1.963M $1.750M
YoY Change 78.9% 12.17% 36.72%
SHAREHOLDERS EQUITY
Retained Earnings -$63.75M -$59.53M -$48.72M
YoY Change 25.79% 22.2% 22.98%
Common Stock $40.48K $40.33K $39.74K
YoY Change 1.85% 1.5% 0.68%
Preferred Stock
YoY Change
Treasury Stock (at cost) $18.93M $18.90M $18.90M
YoY Change 0.0% 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $18.39M $21.90M $29.99M
YoY Change
Total Liabilities & Shareholders Equity $21.30M $23.86M $31.75M
YoY Change -29.17% -24.83% -17.59%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$4.214M -$1.715M -$2.499M
YoY Change 114.99% -31.38% 47.17%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.635M -$4.334M -$1.390M
YoY Change 105.86% 211.81% -9.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $4.500M $4.006M $11.45M
YoY Change 11150.0% -65.02% 801.57%
Cash From Investing Activities $4.500M $4.006M $11.45M
YoY Change 11150.0% -65.02% 801.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 244.5K -590.0 0.000
YoY Change 715.0% -100.0%
NET CHANGE
Cash From Operating Activities -2.635M -4.334M -1.390M
Cash From Investing Activities 4.500M 4.006M 11.45M
Cash From Financing Activities 244.5K -590.0 0.000
Net Change In Cash 2.109M -329.2K 10.06M
YoY Change -274.33% -103.27% -11277.78%
FREE CASH FLOW
Cash From Operating Activities -$2.635M -$4.334M -$1.390M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
280555 USD
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28079157
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40332659
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39747659
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28079157
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27494157
CY2021Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4824215
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4650390
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18900000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13660611 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20637045 USD
CY2021Q3 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
9087199 USD
CY2020Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
8457452 USD
CY2021Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
74793 USD
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
112247 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
179632 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294199 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
569965 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
23572200 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
29781498 USD
CY2021Q3 dyai Prepaid Research And Development In Process Current
PrepaidResearchAndDevelopmentInProcessCurrent
284709 USD
CY2020Q4 dyai Prepaid Research And Development In Process Current
PrepaidResearchAndDevelopmentInProcessCurrent
284709 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6143 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6225 USD
CY2021Q3 us-gaap Assets
Assets
23863052 USD
CY2020Q4 us-gaap Assets
Assets
30072432 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
957802 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1013099 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
842450 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
489756 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
162680 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
123016 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1962932 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1625871 USD
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
40333 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
39748 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
100322444 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98013079 USD
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 USD
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59532742 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50676351 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
21900120 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28446561 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23863052 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30072432 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
692929 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
416361 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2090541 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1256004 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
392544 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
266929 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1612810 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1169351 USD
CY2021Q3 dyai Provision For Contract Losses
ProvisionForContractLosses
0 USD
CY2020Q3 dyai Provision For Contract Losses
ProvisionForContractLosses
112433 USD
dyai Provision For Contract Losses
ProvisionForContractLosses
0 USD
dyai Provision For Contract Losses
ProvisionForContractLosses
187388 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1901548 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
986054 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5918888 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2857670 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1692837 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1643493 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4994458 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4772117 USD
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-30002 USD
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
16240 USD
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-76080 USD
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-26317 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
4016931 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
2992669 USD
us-gaap Costs And Expenses
CostsAndExpenses
12602236 USD
us-gaap Costs And Expenses
CostsAndExpenses
9012843 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3324002 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2576308 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10511695 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7756839 USD
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3202 USD
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
76809 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
49772 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
391779 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1605532 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1605532 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1608734 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
400680 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
68 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2499499 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
76809 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
32093205 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1655304 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
391779 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1715268 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2499499 USD
us-gaap Net Income Loss
NetIncomeLoss
-8856391 USD
us-gaap Net Income Loss
NetIncomeLoss
-7365060 USD
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28079157
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27482157
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27754597
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27467051
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28446561 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
421071 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
115800 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3294949 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25688483 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446120 USD
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
870340 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3846174 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
23158769 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
457209 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-590 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1715268 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
21900120 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
35864471 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
426939 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
175000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2214139 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
34252271 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
436613 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55743 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2651422 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
29994454 USD
us-gaap Net Income Loss
NetIncomeLoss
-8856391 USD
us-gaap Net Income Loss
NetIncomeLoss
-7365060 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1324400 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1264233 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
254193 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
282123 USD
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
1605532 USD
us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
-0 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-76081 USD
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-26317 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-37454 USD
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-223306 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-72051 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
141698 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-0 USD
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-500616 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
289481 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
141550 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
447881 USD
CY2021Q3 dyai Accrued Research And Development In Process Current
AccruedResearchAndDevelopmentInProcessCurrent
344900 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-47033 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-61651 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
352713 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
50745 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
39664 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
75211 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8641881 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5287408 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
11283940 USD
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
14677156 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
10400000 USD
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
36761000 USD
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
1605532 USD
us-gaap Proceeds From Sale Of Equity Securities Fv Ni
ProceedsFromSaleOfEquitySecuritiesFvNi
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
721592 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22083844 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
985550 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
230810 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
985550 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
230810 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-41695 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11791 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6976434 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17039037 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20637045 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4823544 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13660611 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21862581 USD
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
0 USD
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
505616 USD
dyai Number Of Research Organizations
NumberOfResearchOrganizations
3 pure
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For each of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s revenue was generated from eight customers. For the <em style="font: inherit;">nine</em> months ended <em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s revenue was generate<span style="background-color:#ffffff;">d from thirteen and twelve customers, respectively. As of </span><em style="font: inherit;"> September 30, 2021</em><span style="background-color:#ffffff;"> and </span><em style="font: inherit;"> December 31, 2020</em><span style="background-color:#ffffff;">, the Company’s accounts receivable was from five </span><span style="background-color:#ffffff;">and nine customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the <em style="font: inherit;">three</em> months en<span style="background-color:#ffffff;">ded </span><em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em><span style="background-color:#ffffff;">, the Company had five and <em style="font: inherit;">three</em> customers outside of the United States (i.e. European and Asian customers) that accounted for approximately $478,000 or 69.1% and $169,000 or 40.6% of the revenue, respectively. For the <em style="font: inherit;">nine</em> months ended </span><em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em><span style="background-color:#ffffff;">, the Company had seven and <em style="font: inherit;">six</em></span><span style="background-color:#ffffff;"> customers outside of the United States that accounted for approximately $1,599,000 or 76.5% and $609,000 or 48.5% of the revenue, respectively. </span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> September 30, 2021</em>, the Company had four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately $180,000 or 100% of accounts receivable. As of <em style="font: inherit;"> December 31, 2020</em>, the Company had seven customers outside of the United States that accounted for approximately $123,000 or 41.6% of accounts receivable.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. For the <em style="font: inherit;">three</em> months ended </span><em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em><span style="background-color:#ffffff;">, two and one CROs accounted for approximately $1,982,000 or 97.2% and $1,129,000 or 99.5% of total research services we purchased, respectively. For the <em style="font: inherit;">nine</em> months ended </span><em style="font: inherit;"> September 30, 2021 </em>and <em style="font: inherit;">2020</em><span style="background-color:#ffffff;">, three and one CROs accounted for approximately $6,621,000 or 96.9% and $3,602,000 or 96.9% of total research services, respectively. As of </span><em style="font: inherit;"> September 30, 2021</em><span style="background-color:#ffffff;">, two CROs accounted for approximately $768,000 or 80.2% of the accounts payable. As of </span><em style="font: inherit;"> December 31, 2020</em><span style="background-color:#ffffff;">, one CRO accounted for approximately $690,000 or 68.1% of the accounts payable. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.</span></p>
CY2021Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
179632 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294199 USD
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
504690 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
204988 USD
CY2021Q3 dyai Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
40411 USD
CY2020Q4 dyai Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
0 USD
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
24060 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
72403 USD
CY2021Q3 us-gaap Prepaid Taxes
PrepaidTaxes
804 USD
CY2020Q4 us-gaap Prepaid Taxes
PrepaidTaxes
3164 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
569965 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
280555 USD
CY2021Q3 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
767723 USD
CY2020Q4 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
904572 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
174012 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
24496 USD
CY2021Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
16067 USD
CY2020Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
84031 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
957802 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1013099 USD
CY2020Q4 dyai Accrued Research And Development In Process Current
AccruedResearchAndDevelopmentInProcessCurrent
28508 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
86770 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13367 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
842450 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
489756 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
410780 USD
CY2021Q3 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
1700280 USD
CY2020Q3 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
846564 USD
dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
5396227 USD
dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
2431200 USD
CY2021Q3 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
174856 USD
CY2020Q3 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
131553 USD
dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
472605 USD
dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
394706 USD
CY2021Q3 dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
26412 USD
CY2020Q3 dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
7937 USD
dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
50056 USD
dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
31764 USD
CY2021Q3 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
1901548 USD
CY2020Q3 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
986054 USD
dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
5918888 USD
dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
2857670 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20637045 USD
CY2021Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13660611 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13660611 USD
CY2021Q3 dyai Cash Cash Equivalents And Investments Fair Value
CashCashEquivalentsAndInvestmentsFairValue
22740021 USD
CY2021Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
0 USD
CY2021Q3 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
7789 USD
CY2021Q3 us-gaap Investments And Cash
InvestmentsAndCash
22747810 USD
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2021Q3 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
12600000 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
9400000 USD
dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1 pure
CY2021Q3 us-gaap Cash
Cash
1486993 USD
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4824215
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4650390
CY2021Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
12173618 USD
CY2020Q4 us-gaap Cash
Cash
149015 USD
CY2020Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
20488030 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
20637045 USD
CY2020Q4 dyai Cash Cash Equivalents And Investments Fair Value
CashCashEquivalentsAndInvestmentsFairValue
29110506 USD
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
22473 USD
CY2020Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
6463 USD
CY2020Q4 us-gaap Investments And Cash
InvestmentsAndCash
29094496 USD
CY2017Q2 dyai Collaborative Arrangement Payment For Research And Development Agreement
CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
1100000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4824215
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3500516
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
18900000 USD
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0013 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0085 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5452 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.6053 pure
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4638390
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.44
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M20D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13701610 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
770825
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.24
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
585000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M20D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12537900 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y3M10D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11191507 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
457209 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400681 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1324400 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1264233 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.68
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.88
CY2021Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502

Files In Submission

Name View Source Status
0001437749-21-026157-index-headers.html Edgar Link pending
0001437749-21-026157-index.html Edgar Link pending
0001437749-21-026157.txt Edgar Link pending
0001437749-21-026157-xbrl.zip Edgar Link pending
dyai-20200930_g1copy.jpg Edgar Link pending
dyai-20210930.xsd Edgar Link pending
dyai-20210930_cal.xml Edgar Link unprocessable
dyai-20210930_def.xml Edgar Link unprocessable
dyai-20210930_lab.xml Edgar Link unprocessable
dyai-20210930_pre.xml Edgar Link unprocessable
dyai20210930_10q.htm Edgar Link pending
dyai20210930_10q_htm.xml Edgar Link completed
ex_276427.htm Edgar Link pending
ex_276428.htm Edgar Link pending
ex_276429.htm Edgar Link pending
ex_276430.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending